PrimXMAD:PRM -0.37%69 EV-to-FCF is 12.15 as of Jun. 26, 2026, which is 33% below its 10-year median of 18.15. GuruFocus rates XMAD:PRM with a GF Score™ of 69/100 and a GF Value™ of €7.12 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 421 Medical Devices & Instruments companies, Prim ranks better than 76.48% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Prim's Enterprise Value is €220.4 Mil.
Prim's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €18.1 Mil. Therefore, Prim's EV-to-FCF for today is 12.15.
The historical rank and industry rank for Prim's EV-to-FCF or its related term are showing as below:
XMAD:PRM'
s EV-to-FCF Range Over the Past 10 Years
Min: -31.01 Med: 18.15 Max: 2189.24
Current: 11.91
During the past 13 years, the highest EV-to-FCF of Prim was 2189.24. The lowest was -31.01. And the median was 18.15.
XMAD:PRM's EV-to-FCF is ranked better than 76.48% of 421
companies
in the Medical Devices & Instruments industry
Industry Median: 22.82
vs XMAD:PRM: 11.91
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-06-26), Prim's stock price is €13.40.
Prim's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.980. Therefore, Prim's PE Ratio (TTM) for today is 13.67.
Prim (XMAD:PRM) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prim's share price for today is €13.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prim's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.980.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Prim EV-to-FCF Related Terms
Prim EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Prim's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Prim's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prim EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Prim's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Prim's EV-to-FCF falls into.
Prim's current Enterprise Value is €220.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prim's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €18.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prim (XMAD:PRM) has a EV-to-FCF of 12.15 as of Jun. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Prim and its competitors. This is 33% below median its historical median of 18.15. According to the industry distribution chart, Prim ranks #99 out of 421 companies in the Medical Devices & Instruments industry, placing it in the top 23.5%.
Is Prim's EV-to-FCF too high?
Prim's current EV-to-FCF of 12.15 is 33% below median its 10-year median of 18.15. The Medical Devices & Instruments industry median EV-to-FCF is 22.82. Prim's value of 12.15 is 46.8% below this industry median. Based on the distribution chart, Prim ranks #99 out of 421 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Prim has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prim's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Prim ranks #99 out of 421 companies for EV-to-FCF. This places Prim in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 22.82. Prim's value of 12.15 is 46.8% below this benchmark. While the company's 10-year median is 18.15 vs. the industry median of 22.82, Prim has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.82, based on 421 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prim's current EV-to-FCF of 12.15 is 46.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Prim and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prim's current EV-to-FCF is 12.15, which is 33% below median its own 10-year median of 18.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prim stock overvalued right now?
Based on GuruFocus' analysis, Prim (XMAD:PRM) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.12, compared to a current price of €13.40 — trading 88.2% above its estimated fair value. The current EV-to-FCF is 12.15, which is 33% below median its 10-year median of 18.15 and 46.8% below the Medical Devices & Instruments industry median of 22.82. Prim's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Prim (XMAD:PRM), the current EV-to-FCF is 12.15 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prim (XMAD:PRM) Overvalued in 2026?
Based on GuruFocus' analysis, Prim stock appears to be overvalued.
The current stock price of €13.40 is trading 88.2% above its estimated GF Value™ of €7.12.
GuruFocus considers Prim to be Significantly Overvalued.
Key valuation signals for XMAD:PRM:
EV-to-FCF: 12.15 (33% below median its 10-year median of 18.15)
GF Value™: €7.12 vs. price of €13.40 (88.2% above fair value)
Industry Position: 46.8% below the Medical Devices & Instruments median (#99 of 421)
No single metric tells the full story. See the XMAD:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prim SA is engaged in the provision of hospital supplies. The company is in a hospital and orthopedic supplies and materials for physiotherapy, thalassotherapy, thermal therapy, rehabilitation, geriatrics, as well as daily living aids. Prim work across a division of healthcare units such as Operating Theatres; Pain Management Centres; Plastic Surgery; Endosurgery and Cardiovascular.
69GF Score
Get the complete analysis for XMAD:PRM
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PRM has been successfully added to your 
